trials is expected during 2012. Brainsway Ltd. (TASE:BRIN) has received an Investigational Device Exemption (IDE) approval from the FDA, allowing it to begin a multicenter clinical trial to evaluate the efficacy of the Deep TMS device in the treatment of subjects with bipolar disorder. The IDE was granted in respect of 9 medical centers and 120 patients. In addition, the company reported positive results in a safety and efficacy trial of its non-invasive proprietary coil to stimulate the motor cortex for the lower limbs in patients with advanced multiple sclerosis. The double blind trial was conducted by Advanced Technologies Innovation Distribution SrL on 23 patients at INSPE Medical Center in Milan. Half the patients were treated by the device over three weeks, and half received a placebo. Success was measured as the ability to walk ten meters in six minutes, a standard measurement under the Modified Ashworth Scale (MAS). The patients who received the treatment showed a clear statistical improvement compared with the patients who received the placebo. No side effects were recorded.